Evolutionary trade-offs in antibiotic resistance can be modeled and predicted using computational equilibrium concepts from game theory.
Adversarial Debate Score
62% survival rate under critique
Model Critiques
Supporting Research Papers
- Exploiting evolutionary trade-offs to combat antibiotic resistance
Antibiotic resistance frequently evolves through fitness trade-offs in which the genetic alterations that confer resistance to a drug can also cause growth defects in resistant cells. Here, through ex...
- The Fitness Cost of Antibiotic Resistance: A Critical Factor in Bacterial Adaptation
Antibiotic resistance often incurs fitness costs that can impair bacterial growth, competitiveness, or adaptability in drug-free environments. However, these disadvantages are frequently offset by com...
- Identification of Evolutionary Trade‐Offs Associated With High‐Level Colistin Resistance in Acinetobacter baumannii
Colistin (COL) belongs to the polymyxin group of drugs, which possesses a positive charge and interacts with lipopolysaccharide (LPS) of Gram‐negative bacterial outer membranes. Acinetobacter baumanni...
- Identification of Evolutionary Trade-Offs Associated with High-Level Colistin Resistance in Acinetobacter baumannii
Colistin (COL) belongs to the polymyxin group of drugs which possesses a positive charge and interacts with lipopolysaccharide (LPS) of Gram-negative bacterial outer membrane. Additionally, it can pen...
- Pleotropic Effects of Antibiotic Resistance Mutation
Antibiotic resistance mutations (AMRs) alter the phenotypic (physical) characteristics of an organism, which may result in enhanced fitness under antibiotic stress. However, these mutations often infe...
Formal Verification
Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.
This discovery has a Claude-generated validation package with a full experimental design.
Precise Hypothesis
Computational game-theoretic equilibrium models (specifically Nash Equilibrium and Evolutionary Stable Strategy frameworks) can predict the frequency and magnitude of fitness trade-offs in antibiotic-resistant bacterial populations with statistically significant accuracy (R² ≥ 0.70, p < 0.05) compared to empirically measured resistance-fitness cost data across ≥3 antibiotic classes and ≥5 bacterial species, outperforming null models (random drift, simple logistic growth) by a margin of ≥15% in predictive accuracy.
- Game-theoretic equilibrium predictions fail to outperform a null logistic growth model (R² difference < 0.05) across ≥3 independent bacterial species/antibiotic combinations.
- Predicted Nash Equilibria do not correspond to observed stable population frequencies in ≥70% of experimental replicates (p > 0.05 by chi-square goodness-of-fit).
- Fitness trade-off magnitudes predicted by the model deviate from empirical measurements by >30% mean absolute percentage error (MAPE) consistently across datasets.
- Evolutionary Stable Strategies predicted by the model are invaded by alternative strategies in >40% of experimental evolution runs (≥20 replicates, ≥100 generations each).
- Model requires >5 free parameters per species/antibiotic pair to achieve R² ≥ 0.70, indicating overfitting rather than genuine predictive power.
- Predictions fail to generalize across antibiotic classes (e.g., accurate for beta-lactams but not fluoroquinolones), suggesting class-specific artifacts rather than universal principles.
Experimental Protocol
PHASE 1 — Model Construction (Weeks 1–4): Build payoff matrices for 3 bacterial species (E. coli, S. aureus, P. aeruginosa) × 3 antibiotic classes (beta-lactams, fluoroquinolones, aminoglycosides) using published MIC and growth rate data. Implement Nash Equilibrium solver and Replicator Dynamics simulation. Parameterize fitness costs from literature (n ≥ 50 published competition assays per species).
PHASE 2 — In Silico Validation (Weeks 5–8): Run replicator dynamics simulations (10,000 iterations per condition) to predict equilibrium frequencies. Compare predictions against 3 published longitudinal evolution datasets (LTEE, PATRIC database, EUCAST surveillance data). Compute R², MAPE, and Brier scores.
PHASE 3 — Prospective Experimental Validation (Weeks 9–20): Conduct 96-well plate competition assays: 3 species × 3 antibiotics × 4 resistance mechanisms × 8 replicates = 288 experimental units. Measure growth rates at 0, 24, 48, 72 hours. Sequence resistant isolates (Illumina short-read, n=96) to confirm resistance genotypes. Compare observed equilibrium frequencies at generation 50 and 100 against model predictions.
PHASE 4 — Predictive Generalization Test (Weeks 21–24): Apply model trained on E. coli/beta-lactam data to predict outcomes in K. pneumoniae/carbapenem system (held-out validation). Assess transfer accuracy.
- PATRIC (Pathosystems Resource Integration Center) — resistance phenotype + genotype data for >500,000 bacterial isolates (free, public).
- LTEE (Long-Term Evolution Experiment) — Lenski lab E. coli fitness trajectory data, 75,000 generations (free, public).
- EUCAST MIC distribution tables — species-specific MIC breakpoints and distributions (free, public).
- CARD (Comprehensive Antibiotic Resistance Database) — resistance gene ontology and mechanism data (free, public).
- Published competition assay datasets: Andersson & Hughes (2010), Melnyk et al. (2015), Vogwill & MacLean (2015) — fitness cost meta-analysis data.
- Custom experimental data: 288 competition assay measurements (generated in Phase 3).
- Whole-genome sequencing data: 96 isolates × ~5 Mb genome = ~480 Mb raw data (generated in Phase 3).
- Game theory solver: Nashpy (Python), Gambit software suite (free, open-source).
- R² ≥ 0.70 between predicted and observed equilibrium frequencies across ≥18/27 species-antibiotic conditions (p < 0.05, permutation test).
- MAPE ≤ 20% for fitness trade-off magnitude predictions across all experimental conditions.
- Nash Equilibrium predictions match observed stable population frequencies within ±10% in ≥75% of experimental replicates (288 assays).
- Game-theoretic model outperforms logistic growth null model by ≥15% in R² across all conditions.
- Evolutionary Stable Strategies correctly predict invasion resistance in ≥80% of experimental evolution replicates.
- Model generalizes to held-out K. pneumoniae/carbapenem system with R² ≥ 0.60 (transfer accuracy criterion).
- Bayesian posterior predictive intervals capture observed data in ≥90% of cases (calibration criterion).
- Sensitivity analysis shows model is robust to ±20% parameter perturbation (prediction change < 15%).
- R² < 0.50 across ≥50% of species-antibiotic conditions after full parameterization.
- MAPE > 35% for fitness trade-off predictions in ≥2 of 3 bacterial species.
- Game-theoretic model performs no better than random frequency assignment (p > 0.10 on permutation test) in ≥3 conditions.
-
40% of predicted Nash Equilibria are not observed experimentally (chi-square p < 0.05 for deviation).
- Model requires >8 free parameters per condition to achieve R² ≥ 0.60, indicating overfitting.
- Transfer to K. pneumoniae/carbapenem system yields R² < 0.40, indicating no generalization.
- Contamination or plasmid transfer events invalidate >20% of competition assay replicates.
- Sequencing reveals unexpected resistance mechanisms in >30% of isolates, invalidating payoff matrix assumptions.
48
GPU hours
168d
Time to result
$18,500
Min cost
$87,000
Full cost
ROI Projection
- DIAGNOSTIC TOOLS: Resistance evolution prediction software for clinical microbiology labs; market size ~$1.2B (antimicrobial susceptibility testing market, 2023); potential SaaS licensing at $50K–200K per hospital system annually.
- PHARMACEUTICAL: Antibiotic combination optimization platform for pharma R&D; licensing value $5–50M per partnership; applicable to 15+ companies with active antibiotic pipelines.
- HOSPITAL SYSTEMS: Infection control decision support integration into EMR systems (Epic, Cerner); potential $10–30M acquisition target for health IT companies.
- AGRICULTURAL: Veterinary antibiotic stewardship applications (livestock resistance management); $800M global veterinary antimicrobial market.
- BIODEFENSE: BARDA/DoD interest in resistance prediction for biodefense preparedness; contract value $2–10M.
- ACADEMIC LICENSING: Software toolkit licensing to research institutions; $500K–2M cumulative over 10 years.
- TOTAL ADDRESSABLE MARKET (conservative): $50–200M over 10 years if commercialized as integrated resistance prediction platform.
🔓 If proven, this unlocks
Proving this hypothesis is a prerequisite for the following downstream discoveries and applications:
- 1adaptive-antibiotic-cycling-game-theoretic-optimization
- 2personalized-resistance-evolution-prediction-clinical
- 3multi-drug-combination-nash-equilibrium-therapy-design
- 4evolutionary-trap-antibiotic-resistance-reversal
- 5game-theoretic-hospital-infection-control-policy
- 6resistance-evolution-forecasting-surveillance-integration
Prerequisites
These must be validated before this hypothesis can be confirmed:
- empirical-fitness-cost-database-antibiotic-resistance-2024
- game-theory-evolutionary-dynamics-microbial-validation
- patric-resistance-phenotype-genotype-linkage-study
- ltee-fitness-trajectory-quantification-2023
Implementation Sketch
# Evolutionary Game Theory - Antibiotic Resistance Prediction Framework # Architecture Overview import numpy as np import nashpy as nash from scipy.integrate import odeint import pymc3 as pm from sklearn.metrics import r2_score, mean_absolute_percentage_error # ============================================================ # MODULE 1: PAYOFF MATRIX CONSTRUCTION # ============================================================ class ResistancePayoffMatrix: """ Constructs payoff matrices from empirical fitness cost data. Strategies: [Susceptible, Resistant, Compensatory_Mutant, Multi_Resistant] """ def __init__(self, species, antibiotic_class): self.species = species self.antibiotic_class = antibiotic_class self.strategies = ['S', 'R', 'CM', 'MR'] def build_from_literature(self, fitness_cost_db): # fitness_cost_db: DataFrame with columns [species, mechanism, growth_rate, MIC] # Returns: NxN payoff matrix where entry [i,j] = fitness of strategy i vs strategy j payoff_matrix = np.zeros((4, 4)) for i, strat_i in enumerate(self.strategies): for j, strat_j in enumerate(self.strategies): payoff_matrix[i,j] = self._compute_payoff( strat_i, strat_j, fitness_cost_db ) return payoff_matrix def _compute_payoff(self, s_i, s_j, db): # Payoff = growth_rate_i * (1 - fitness_cost_i) * antibiotic_effect(s_i, s_j) # antibiotic_effect depends on MIC ratio and environmental antibiotic concentration base_growth = db.loc[(db.species==self.species) & (db.strategy==s_i), 'growth_rate'].mean() fitness_cost = db.loc[(db.species==self.species) & (db.strategy==s_i), 'fitness_cost'].mean() mic_ratio = self._get_mic_ratio(s_i, s_j, db) return base_growth * (1 - fitness_cost) * mic_ratio # ============================================================ # MODULE 2: NASH EQUILIBRIUM SOLVER # ============================================================ class NashEquilibriumSolver: def __init__(self, payoff_matrix_A, payoff_matrix_B=None): # For symmetric games, B = A.T self.A = payoff_matrix_A self.B = payoff_matrix_B if payoff_matrix_B is not None else payoff_matrix_A.T self.game = nash.Game(self.A, self.B) def find_all_equilibria(self): equilibria = list(self.game.support_enumeration()) return equilibria # List of (sigma_1, sigma_2) mixed strategy pairs def find_ess(self, equilibria): # Evolutionary Stable Strategy: NE that satisfies second-order stability ess_candidates = [] for eq in equilibria: sigma = eq[0] if self._is_ess(sigma): ess_candidates.append(sigma) return ess_candidates def _is_ess(self, sigma): # ESS condition: for all mutant strategies m != sigma, # u(sigma, sigma) > u(m, sigma) OR # [u(sigma, sigma) == u(m, sigma) AND u(sigma, m) > u(m, m)] n_strategies = len(sigma) for mutant_idx in range(n_strategies): if sigma[mutant_idx] < 1e-6: # Not in support mutant = np.zeros(n_strategies) mutant[mutant_idx] = 1.0 u_sigma_sigma = sigma @ self.A @ sigma u_mutant_sigma = mutant @ self.A @ sigma if u_mutant_sigma >= u_sigma_sigma: return False return True # ============================================================ # MODULE 3: REPLICATOR DYNAMICS SIMULATION # ============================================================ class ReplicatorDynamics: def __init__(self, payoff_matrix, n_strategies): self.A = payoff_matrix self.n = n_strategies def dynamics(self, x, t): # dx_i/dt = x_i * [(Ax)_i - x^T A x] Ax = self.A @ x avg_fitness = x @ Ax dxdt = x * (Ax - avg_fitness) return dxdt def simulate(self, x0, t_span, n_points=1000): t = np.linspace(0, t_span, n_points) trajectory = odeint(self.dynamics, x0, t) equilibrium = trajectory[-1] # Final state return trajectory, equilibrium def run_ensemble(self, n_initial_conditions=100, t_span=500): equilibria = [] for _ in range(n_initial_conditions): # Random initial frequencies (Dirichlet distribution) x0 = np.random.dirichlet(np.ones(self.n)) _, eq = self.simulate(x0, t_span) equilibria.append(eq) return np.array(equilibria) # ============================================================ # MODULE 4: BAYESIAN PARAMETER ESTIMATION # ============================================================ class BayesianPayoffEstimator: def __init__(self, observed_frequencies, prior_fitness_costs): self.observed = observed_frequencies self.priors = prior_fitness_costs def fit(self, n_samples=2000, n_chains=4): with pm.Model() as model: # Priors on fitness costs from literature fitness_cost = pm.Normal('fitness_cost', mu=self.priors['mean'], sigma=self.priors['std'], shape=len(self.priors['mean'])) # Likelihood: observed frequencies ~ Dirichlet(predicted_equilibrium) predicted_eq = pm.Deterministic('predicted_eq', self._compute_equilibrium(fitness_cost)) obs = pm.Dirichlet('obs', a=predicted_eq * 100, observed=self.observed) trace = pm.sample(n_samples, chains=n_chains, return_inferencedata=True) return trace def _compute_equilibrium(self, fitness_cost): # Differentiable equilibrium computation for gradient-based sampling # Simplified: returns softmax of fitness-adjusted payoffs adjusted_payoffs = pm.math.softmax(-fitness_cost) return adjusted_payoffs # ============================================================ # MODULE 5: VALIDATION AND METRICS # ============================================================ class ModelValidator: def __init__(self, predictions, observations): self.pred = predictions self.obs = observations def compute_metrics(self): metrics = { 'r2': r2_score(self.obs, self.pred), 'mape': mean_absolute_percentage_error(self.obs, self.pred), 'pearson_r': np.corrcoef(self.obs, self.pred)[0,1], 'mean_abs_error': np.mean(np.abs(self.obs - self.pred)) } return metrics def permutation_test(self, n_permutations=10000): observed_r2 = r2_score(self.obs, self.pred) null_r2s = [] for _ in range(n_permutations): shuffled_pred = np.random.permutation(self.pred) null_r2s.append(r2_score(self.obs, shuffled_pred)) p_value = np.mean(np.array(null_r2s) >= observed_r2) return p_value, observed_r2, np.array(null_r2s) def compare_to_null_model(self, null_predictions): null_r2 = r2_score(self.obs, null_predictions) model_r2 = r2_score(self.obs, self.pred) improvement = (model_r2 - null_r2) / max(abs(null_r2), 1e-6) return {'null_r2': null_r2, 'model_r2': model_r2, 'relative_improvement': improvement} # ============================================================ # MODULE 6: MAIN PIPELINE # ============================================================ def run_validation_pipeline(species_list, antibiotic_list, fitness_db, experimental_data): results = {} for species in species_list: # ['E.coli', 'S.aureus', 'P.aeruginosa'] for antibiotic in antibiotic_list: # ['beta-lactam', 'fluoroquinolone', 'aminoglycoside'] condition = f"{species}_{antibiotic}" # Step 1: Build payoff matrix rpm = ResistancePayoffMatrix(species, antibiotic) A = rpm.build_from_literature(fitness_db) # Step 2: Find Nash Equilibria nes = NashEquilibriumSolver(A) equilibria = nes.find_all_equilibria() ess = nes.find_ess(equilibria) # Step 3: Simulate replicator dynamics rd = ReplicatorDynamics(A, n_strategies=4) trajectories = rd.run_ensemble(n_initial_conditions=100) predicted_eq = np.median(trajectories, axis=0) # Step 4: Bayesian refinement obs_freq = experimental_data[condition]['frequencies'] priors = fitness_db.get_priors(species, antibiotic) bpe = BayesianPayoffEstimator(obs_freq, priors) trace = bpe.fit() # Step 5: Validate validator = ModelValidator(predicted_eq, obs_freq) metrics = validator.compute_metrics() p_val, obs_r2, null_dist = validator.permutation_test() results[condition] = { 'nash_equilibria': equilibria, 'ess': ess, 'predicted_frequencies': predicted_eq, 'metrics': metrics, 'p_value': p_val, 'bayesian_trace': trace } return results # ============================================================ # EXECUTION # ============================================================ # species_list = ['E.coli', 'S.aureus', 'P.aeruginosa'] # antibiotic_list = ['beta-lactam', 'fluoroquinolone', 'aminoglycoside'] # results = run_validation_pipeline(species_list, antibiotic_list, # fitness_db, experimental_data) # Generate summary report with all metrics and visualizations
CHECKPOINT 1 (End of Week 4 — Model Construction): ABORT IF: Nash Equilibrium solver fails to converge for >30% of payoff matrices derived from literature data, OR Bayesian parameter estimation yields posterior distributions with R-hat > 1.1 for >50% of parameters. ACTION: Simplify to 2-strategy games; reduce model dimensionality.
CHECKPOINT 2 (End of Week 8 — In Silico Validation): ABORT IF: R² < 0.40 against LTEE and PATRIC validation datasets across all conditions, OR game-theoretic model performs no better than null model (p > 0.20 on permutation test) in ≥5/9 conditions. ACTION: Reassess payoff matrix construction methodology; consider alternative equilibrium concepts (correlated equilibrium, quantal response equilibrium) before proceeding to wet lab.
CHECKPOINT 3 (End of Week 12 — Early Experimental Results): ABORT IF: >25% of competition assays show contamination or anomalous growth curves (OD600 trajectories inconsistent with expected growth phases), OR preliminary frequency measurements (n=48 assays) show MAPE > 50% against model predictions. ACTION: Troubleshoot assay protocol; replace contaminated strains; reassess whether experimental system matches model assumptions.
CHECKPOINT 4 (End of Week 16 — Full Experimental Dataset): ABORT IF: R² < 0.50 across ≥60% of species-antibiotic conditions with full experimental data, OR >35% of predicted Nash Equilibria are not observed experimentally. ACTION: Conduct root cause analysis; determine whether failure is in model structure, parameterization, or experimental system; consider publishing negative result with mechanistic explanation.
CHECKPOINT 5 (End of Week 20 — Sequencing Analysis): ABORT IF: Sequencing reveals that >30% of resistant isolates carry unexpected resistance mechanisms not present in payoff matrix (e.g., novel efflux pumps, unexpected plasmid acquisition), invalidating model assumptions. ACTION: Update payoff matrices with newly discovered mechanisms; re-run predictions; extend timeline by 4 weeks for model revision.
CHECKPOINT 6 (End of Week 23 — Transfer Validation): ABORT GENERALIZATION CLAIM IF: Transfer to K. pneumoniae/carbapenem system yields R² < 0.40. ACTION: Downgrade claim from "universal framework" to "species-specific model"; revise manuscript scope accordingly; do not abort entire study.